Abstract library

45 results for "177Lu-DOTATOC".
#2838 Accidental Injection of Unlabeled Lu-177 Caused Catastrophic Consequences in Patients with Neuroendocrine Tumor
Introduction: Since Lu-177 DOTATATE treatment is not approved in South Korea, patients with neuroendocrine tumors were sent to Germany and Malaysia for the treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Professor Keon Wook Kang
Authors: Kang K W, Song Y S, Kwon T E, Ha W H, ...
#2744 Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review
Introduction: PRRT is an effective treatment for well-differentiated NET, but immediate adverse events during or shortly after administration of the treatment are not well defined.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christopher Wee
Authors: Wee C, Dundar A, Packard A, Kendi A T, ...
#2847 Surgical and Survival Outcomes of Early Peptide Receptor Radionuclide Therapy for Downstaging Locally Advanced or Oligometastatic Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD Noémie S Minczeles
#2863 Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Federica Scalorbi
#2917 Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors
Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Markus Galler
Authors: Galler M, Schatka I, Buch F, Bluemel S, ...
#3019 Incomplete Peptide Receptor Radionuclide Therapy Courses - Are We Selecting Our Patients Appropriately?
Introduction: As per recommendations, a Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE course usually consists of 4 cycles. Patients may discontinue a PRRT course early, either due to progression or toxicity. Limited data are available about predictive factors for PRRT early discontinuation.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Julian Gertner
Authors: Gertner J, Groves J, Aziz B, Miah L, ...
Keywords: prrt
#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)
Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Minseok Suh
Authors: Suh M, Cheon G J, Lee D S, ...
#68 Serum chromogranin A as tumor marker in neuroendocrine tumors
Introduction: Serum chromogranin A (CgA) is used as a tumor marker for neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Svenja Nölting
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad